SBIR/STTR Research Award
An Integrated Neurochemical/Electrophysiological Recording and Neuromodulation System for Basic and Clinical Research
Award amount
$438,792Program and phase
STTR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Wincs International, LLC
- Proposal award date
- 2022-09-12
- Contract end date
- 2023-08-31
- UEI
- UBXPYE6HUL84
- Solicitation number
- PA21-262
- Topic code
- 107
Research abstract
PROJECT SUMMARY
WINCS International LLC, in partnership with Mayo Clinic, proposes to develop and demonstrate a highly
innovative next-generation clinical instrument together with custom user-friendly display and analysis software.
For the first time, the Multifunctional Apparatus for Voltammetry, Electrophysiology, and Neuromodulation
(MAVEN) will offer wireless voltammetric sensing of multiple neurotransmitters (e.g., dopamine, serotonin, and
adenosine) at carbon-fiber microelectrodes. MAVEN can be applied to a broad range of clinical neuroscience
research subjects involving brain neurosurgeries. Alongside these multiple neurochemical sensing capabilities,
the device will be capable of near-simultaneous electrophysiological (e.g., action and local field potentials)
recordings. The main innovation of the MAVEN system is to include state-of-the-art voltammetric techniques to
quantitatively measure both phasic (stimulation-induced) and tonic (resting) concentration levels of
neurochemicals in real-time and near-simultaneously with other recording modalities. This capability is
currently unavailable in clinical neuroscience research. In addition, multiple cyclic square wave voltammetry
(MCSWV) will enable second-to-second quantitative measurements of tonic extracellular levels of dopamine
and serotonin with exceptional spatial resolution, sensitivity, specificity, and minimal tissue disturbance. This
proposal employs our unique combined expertise in neuroscience, electrochemistry, engineering, and software
development to validate this novel clinical research instrument in preparation for its use during intraoperative
clinical neurosurgeries. Also, combining electrophysiology and electrochemical technologies would enable
investigators to probe unexplored links between the abnormal activity of neural elements and the
dopaminergic, serotonergic, purinergic (adenosine) dynamics associated with neuropsychopathologies, such
as Parkinson’s disease, essential tremor, obsessive-compulsive disorder, depression, and epilepsy. Our large
animal model (swine) studies emulating existing human intraoperative neurosurgical procedures will provide
essential information to guide and inform the finalization of the MAVEN design for use by the clinical
neuroscience community in future IDE-enabled mechanistic clinical studies.
Our proposal seeks to (1) finalize the development of MAVEN, together with a sophisticated user-friendly
software interface that (2) meets device manufacturing processes, regulatory Design Control, and medical
safety requirements to obtain an FDA-approved Investigational Device Exemption (IDE), and (3) use a swine
model to develop MAVEN stimulation and recording protocols for use in existing intraoperative neurosurgical
procedures (e.g., deep brain stimulation neurosurgeries and cortical lobectomies). This includes demonstrating
the functionality, versatility, and efficacy of the MAVEN system for future pre-clinical and clinical neuroscience
research.PROJECT NARRATIVE
The proposed studies consist of three Aims in which, in Aim 1, WINCS International LLC, in partnership with
Mayo Clinic Neural Engineering Laboratories and Division of Engineering, will finalize the development of a
novel neurochemical/electrophysiological recording and stimulating instrument, called Multifunctional
Apparatus for Voltammetry, Electrophysiology and Neuromodulation (MAVEN), together with a sophisticated
user-friendly software interface, for a broad range of clinical neuroscience research in subjects undergoing
intraoperative brain neurosurgeries. In Aim 2, overall development and construction plans for the MAVEN
system will ensure that device manufacturing processes and design history files meet regulatory Design
Control and medical safety requirements necessary to obtain approval for an FDA Investigational Device
Exemption (IDE). Aim 3 is designed to integrate several MAVEN recording protocols into existing intraoperative
clinical neurosurgical procedures (e.g., deep brain stimulation neurosurgeries and cortical lobectomies) using a
large animal model (swine), including confirming MAVEN’s ability to reliably record neurochemical and
electrophysiological events (e.g., dopamine, serotonin, and adenosine, and action/local field potential activity,
respectively) for future use of the system in IDE-enabled mechanistic clinical studies.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity
- A Digital Biomarker for ALS - Pison Neural Biosensor
- Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
- Development of a novel oral brain penetrant therapeutic for ALS disease
- Engineering a Middle Meningeal Artery Embolization Model with Hydrophilicity and Hydraulic Resistance